Kirtane AJ, et al. - In a prospective, observational study performed at 116 U.S. sites, the RESOLUTE US trial, researchers evaluated the Resolute zotarolimus-eluting stent (R-ZES) with respect to its long-term safety and efficacy. Participants were patients with de novo coronary lesions, who were observed clinically for 5 years with independent event adjudication and data monitoring. Of 1,402 patients (1,573 lesions) included, the presence of diabetes mellitus and ACC type B2/C lesions was reported in 34% and 75%, respectively. Among a relatively low-risk population of patients in this fully adjudicated and monitored RESOLUTE US trial, the R-ZES stent displayed long-term 5-year safety and efficacy. At 5 years, the rate of stent thrombosis was 0.5%. Diabetes mellitus, prior coronary artery bypass grafting, prior myocardial infarction, and smaller reference vessel diameter were identified as covariates independently related to 5-year target lesion failure in multivariable analysis.